Please enable Javascript
Rebecca Araujo
Articles by Rebecca Araujo
Evaluating First-line Dostarlimab Versus Pembrolizumab With Chemotherapy in mNSCLC
Rebecca Araujo
Non-Small Cell Lung Cancer
|
November 17, 2023
In patients with metastatic nonsquamous NSCLC, pembrolizumab plus chemotherapy showed clinical efficacy.
Read More
Relationship Identified Between Depression and Lung Cancer Survival
Rebecca Araujo
Non-Small Cell Lung Cancer
|
September 21, 2023
Patients with advanced lung cancer and depression whose depressive symptoms increased after diagnosis were found to have ...
Read More
Checkpoint Inhibitors Plus Cell Therapy for NSCLC Reduces Tumor Progression
Rebecca Araujo
Non-Small Cell Lung Cancer
|
September 21, 2023
Adoptive cell therapy in combination with checkpoint inhibitors may be promising new treatment for patients with ...
Read More
World Lung Cancer Day: Education, Advocacy, and Remembrance
Rebecca Araujo
Lung Cancer
|
September 21, 2023
August 1 is World Lung Cancer Day—a day where patients, physicians, and cancer organizations around the globe educate ...
Read More
More Than 10% of Patients With Lung Cancer Don’t Know Their Cancer Type
Rebecca Araujo
Lung Cancer
|
September 21, 2023
More than ten percent of patients with lung cancer do not know what type they have, according to a new study from ...
Read More
Amivantamab Seeks FDA Nod for Non-Small Cell Lung Cancer
Rebecca Araujo
Non-Small Cell Lung Cancer
|
September 21, 2023
Janssen Pharmaceuticals has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...
Read More
Women Have Better Survival Than Men After Lung Cancer Surgery
Rebecca Araujo
Lung Cancer
|
September 21, 2023
Findings from a new study published in Chest suggested that women had better survival rates after lung cancer surgery ...
Read More
First-Line Lorlatinib Improves Survival and Metastasis in Advanced ALK-Positive Lung Cancer
Rebecca Araujo
Non-Small Cell Lung Cancer
|
November 19, 2020
Early treatment with the anaplastic lymphoma kinase (ALK)-inhibitor lorlatinib reduced cancer progression and death in ...
Read More